{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:19:40Z","timestamp":1781104780350,"version":"3.54.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,12,14]],"date-time":"2017-12-14T00:00:00Z","timestamp":1513209600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"The National Key Research and Development Program of China","award":["2016YFD0050405"],"award-info":[{"award-number":["2016YFD0050405"]}]},{"name":"Natural Science Foundation of Guangdong Province, China","award":["2014A030307042"],"award-info":[{"award-number":["2014A030307042"]}]},{"name":"Medical Scientific Research Foundation of Guangdong Province, China","award":["A2016306"],"award-info":[{"award-number":["A2016306"]}]},{"name":"Natural Science Foundation of Guangdong Province, China","award":["2016A030307031"],"award-info":[{"award-number":["2016A030307031"]}]},{"name":"he National Key Research and Development Program of China","award":["2017YFD0501705"],"award-info":[{"award-number":["2017YFD0501705"]}]},{"name":"Medical Scientific Research Foundation of Guangdong Province, China","award":["A2017404"],"award-info":[{"award-number":["A2017404"]}]},{"name":"Key Scientific and Technological Project of Meizhou People's Hospital (Huangtang Hospital), Meizhou Hospital Affiliated to Sun Yat-sen University, Guangdong Province, China","award":["MPHKSTP-20170102"],"award-info":[{"award-number":["MPHKSTP-20170102"]}]},{"name":"Key Scientific and Technological Project of Meizhou People's Hospital (Huangtang Hospital), Meizhou Hospital Affiliated to Sun Yat-sen University, Guangdong Province, China","award":["MPHKSTP-20170101"],"award-info":[{"award-number":["MPHKSTP-20170101"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s00228-017-2393-1","type":"journal-article","created":{"date-parts":[[2017,12,14]],"date-time":"2017-12-14T08:34:31Z","timestamp":1513240471000},"page":"423-431","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China"],"prefix":"10.1007","volume":"74","author":[{"given":"Zhixiong","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyuan","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunren","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhidong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebo","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaocai","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingsen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,14]]},"reference":[{"issue":"3","key":"2393_CR1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/cge.12881","volume":"91","author":"M Zaiou","year":"2017","unstructured":"Zaiou M, El Amri H (2017) Cardiovascular pharmacogenetics: a promise for genomically-guided therapy and personalized medicine. Clin Genet 91(3):355\u2013370. https:\/\/doi.org\/10.1111\/cge.12881","journal-title":"Clin Genet"},{"issue":"16","key":"2393_CR2","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1056\/NEJMoa060989","volume":"354","author":"DL Bhatt","year":"2006","unstructured":"Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354(16):1706\u20131717. https:\/\/doi.org\/10.1056\/NEJMoa060989","journal-title":"N Engl J Med"},{"issue":"4","key":"2393_CR3","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa0809171","volume":"360","author":"JL Mega","year":"2009","unstructured":"Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360(4):354\u2013362. https:\/\/doi.org\/10.1056\/NEJMoa0809171","journal-title":"N Engl J Med"},{"issue":"16","key":"2393_CR4","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1001\/jama.2010.1543","volume":"304","author":"JL Mega","year":"2010","unstructured":"Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS (2010) Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304(16):1821\u20131830. https:\/\/doi.org\/10.1001\/jama.2010.1543","journal-title":"JAMA"},{"issue":"4","key":"2393_CR5","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1046\/j.0306-5251.2001.01499.x","volume":"52","author":"JA Goldstein","year":"2001","unstructured":"Goldstein JA (2001) Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52(4):349\u2013355. https:\/\/doi.org\/10.1046\/j.0306-5251.2001.01499.x","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"2393_CR6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1177\/0091270008315310","volume":"48","author":"DS Small","year":"2008","unstructured":"Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, Salazar DE, Winters KJ (2008) Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 48(4):475\u2013484. https:\/\/doi.org\/10.1177\/0091270008315310","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"2393_CR7","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1182\/blood-2006-04-013052","volume":"108","author":"JS Hulot","year":"2006","unstructured":"Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108(7):2244\u20132247. https:\/\/doi.org\/10.1182\/blood-2006-04-013052","journal-title":"Blood"},{"issue":"4","key":"2393_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jacc.2010.05.013","volume":"56","author":"DR Holmes Jr","year":"2010","unstructured":"Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM (2010) ACCF\/AHA clopidogrel clinical alert: approaches to the FDA \u201cboxed warning\u201d: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 56(4):321\u2013341. https:\/\/doi.org\/10.1016\/j.jacc.2010.05.013","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2393_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/gim.2014.76","volume":"17","author":"RL Osnabrugge","year":"2015","unstructured":"Osnabrugge RL, Head SJ, Zijlstra F, ten Berg JM, Hunink MG, Kappetein AP, Janssens AC (2015) A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users. Genet Med 17(1):3\u201311. https:\/\/doi.org\/10.1038\/gim.2014.76","journal-title":"Genet Med"},{"issue":"3","key":"2393_CR10","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.thromres.2014.12.007","volume":"135","author":"L Zhang","year":"2015","unstructured":"Zhang L, Yang J, Zhu X, Wang X, Peng L, Li X, Cheng P, Yin T (2015) Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention\u2014a systematic review and meta-analysis. Thromb Res 135(3):449\u2013458. https:\/\/doi.org\/10.1016\/j.thromres.2014.12.007","journal-title":"Thromb Res"},{"issue":"2","key":"2393_CR11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/hrt.2011.227652","volume":"98","author":"M Zabalza","year":"2012","unstructured":"Zabalza M, Subirana I, Sala J, Lluis-Ganella C, Lucas G, Tomas M, Masia R, Marrugat J, Brugada R, Elosua R (2012) Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart 98(2):100\u2013108. https:\/\/doi.org\/10.1136\/hrt.2011.227652","journal-title":"Heart"},{"issue":"8","key":"2393_CR12","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jama.2009.1232","volume":"302","author":"AR Shuldiner","year":"2009","unstructured":"Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302(8):849\u2013857. https:\/\/doi.org\/10.1001\/jama.2009.1232","journal-title":"JAMA"},{"issue":"1","key":"2393_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ahj.2014.03.006","volume":"168","author":"PW Janssen","year":"2014","unstructured":"Bergmeijer TO, Janssen PW, Schipper JC, Qaderdan K, Ishak M, Ruitenbeek RS, Asselbergs FW, van \u2018t Hof AW, Dewilde WJ, Spano F, Herrman JP, Kelder JC, Postma MJ, de Boer A, Deneer VH, ten Berg JM (2014) CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients\u2014rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. Am Heart J 168(1):16\u201322 e11. https:\/\/doi.org\/10.1016\/j.ahj.2014.03.006","journal-title":"Am Heart J"},{"issue":"6","key":"2393_CR14","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1161\/CIRCGENETICS.114.000669","volume":"7","author":"MJ Sorich","year":"2014","unstructured":"Sorich MJ, Rowland A, McKinnon RA, Wiese MD (2014) CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis. Circ Cardiovasc Genet 7(6):895\u2013902. https:\/\/doi.org\/10.1161\/CIRCGENETICS.114.000669","journal-title":"Circ Cardiovasc Genet"},{"issue":"8","key":"2393_CR15","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1177\/0091270009355161","volume":"50","author":"M Man","year":"2010","unstructured":"Man M, Farmen M, Dumaual C, Teng CH, Moser B, Irie S, Noh GJ, Njau R, Close S, Wise S, Hockett R (2010) Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol 50(8):929\u2013940. https:\/\/doi.org\/10.1177\/0091270009355161","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"2393_CR16","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1056\/NEJMra1010600","volume":"364","author":"L Wang","year":"2011","unstructured":"Wang L, McLeod HL, Weinshilboum RM (2011) Genomics and drug response. N Engl J Med 364(12):1144\u20131153. https:\/\/doi.org\/10.1056\/NEJMra1010600","journal-title":"N Engl J Med"},{"issue":"5","key":"2393_CR17","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood-2014-01-512723","volume":"124","author":"NC Chan","year":"2014","unstructured":"Chan NC, Eikelboom JW, Ginsberg JS, Lauw MN, Vanassche T, Weitz JI, Hirsh J (2014) Role of phenotypic and genetic testing in managing clopidogrel therapy. Blood 124(5):689\u2013699. https:\/\/doi.org\/10.1182\/blood-2014-01-512723","journal-title":"Blood"},{"issue":"10","key":"2393_CR18","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2016.101","volume":"13","author":"EM Antman","year":"2016","unstructured":"Antman EM, Loscalzo J (2016) Precision medicine in cardiology. Nat Rev Cardiol 13(10):591\u2013602. https:\/\/doi.org\/10.1038\/nrcardio.2016.101","journal-title":"Nat Rev Cardiol"},{"issue":"11","key":"2393_CR19","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/j.cjca.2013.07.001","volume":"29","author":"JF Tanguay","year":"2013","unstructured":"Tanguay JF, Bell AD, Ackman ML, Bauer RD, Cartier R, Chan WS, Douketis J, Roussin A, Schnell G, Verma S, Wong G, Mehta SR (2013) Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. Can J Cardiol 29(11):1334\u20131345. https:\/\/doi.org\/10.1016\/j.cjca.2013.07.001","journal-title":"Can J Cardiol"},{"issue":"1","key":"2393_CR20","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S0022-3565(24)36606-6","volume":"281","author":"ZS Xiao","year":"1997","unstructured":"Xiao ZS, Goldstein JA, Xie HG, Blaisdell J, Wang W, Jiang CH, Yan FX, He N, Huang SL, ZH X, Zhou HH (1997) Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 281(1):604\u2013609","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"2393_CR21","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/j.1365-2125.2004.02144.x","volume":"58","author":"YS Pang","year":"2004","unstructured":"Pang YS, Wong LP, Lee TC, Mustafa AM, Mohamed Z, Lang CC (2004) Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects. Br J Clin Pharmacol 58(3):332\u2013335. https:\/\/doi.org\/10.1111\/j.1365-2125.2004.02144.x","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"2393_CR22","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/clpt.2013.105","volume":"94","author":"SA Scott","year":"2013","unstructured":"Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR (2013) Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 94(3):317\u2013323. https:\/\/doi.org\/10.1038\/clpt.2013.105","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"2393_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cpt.147","volume":"98","author":"JK Hicks","year":"2015","unstructured":"Hicks JK, Bishop JR, Sangkuhl K, Muller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, LL A, Skaar TC, Scott SA, Stingl JC, Klein TE, Caudle KE, Gaedigk A (2015) Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther 98(2):127\u2013134. https:\/\/doi.org\/10.1002\/cpt.147","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"2393_CR24","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S0009-9236(98)90037-6","volume":"63","author":"JK Lamba","year":"1998","unstructured":"Lamba JK, Dhiman RK, Kohli KK (1998) Genetic polymorphism of the hepatic cytochrome P450 2C19 in north Indian subjects. Clin Pharmacol Ther 63(4):422\u2013427. https:\/\/doi.org\/10.1016\/S0009-9236(98)90037-6","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2393_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/00008571-199702000-00008","volume":"7","author":"JA Goldstein","year":"1997","unstructured":"Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA (1997) Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7(1):59\u201364. https:\/\/doi.org\/10.1097\/00008571-199702000-00008","journal-title":"Pharmacogenetics"},{"issue":"4","key":"2393_CR26","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0009-9236(98)90070-4","volume":"64","author":"K Herrlin","year":"1998","unstructured":"Herrlin K, Massele AY, Jande M, Alm C, Tybring G, Abdi YA, Wennerholm A, Johansson I, Dahl ML, Bertilsson L, Gustafsson LL (1998) Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin Pharmacol Ther 64(4):391\u2013401. https:\/\/doi.org\/10.1016\/S0009-9236(98)90070-4","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"2393_CR27","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1046\/j.1365-2125.2003.01937.x","volume":"56","author":"AC Allabi","year":"2003","unstructured":"Allabi AC, Gala JL, Desager JP, Heusterspreute M, Horsmans Y (2003) Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol 56(6):653\u2013657. https:\/\/doi.org\/10.1046\/j.1365-2125.2003.01937.x","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"2393_CR28","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0009-9236(96)90214-3","volume":"60","author":"T Kubota","year":"1996","unstructured":"Kubota T, Chiba K, Ishizaki T (1996) Genotyping of S-mephenytoin 4\u2032-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 60(6):661\u2013666. https:\/\/doi.org\/10.1016\/S0009-9236(96)90214-3","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"2393_CR29","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/clpt.1985.194","volume":"38","author":"K Nakamura","year":"1985","unstructured":"Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA (1985) Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38(4):402\u2013408. https:\/\/doi.org\/10.1038\/clpt.1985.194","journal-title":"Clin Pharmacol Ther"},{"issue":"9660","key":"2393_CR30","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","volume":"373","author":"JP Collet","year":"2009","unstructured":"Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot G (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373(9660):309\u2013317. https:\/\/doi.org\/10.1016\/S0140-6736(08)61845-0","journal-title":"Lancet"},{"issue":"20","key":"2393_CR31","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","volume":"51","author":"D Trenk","year":"2008","unstructured":"Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Buttner HJ, Neumann FJ (2008) Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51(20):1925\u20131934. https:\/\/doi.org\/10.1016\/j.jacc.2007.12.056","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2393_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059344","volume":"8","author":"X Xie","year":"2013","unstructured":"Xie X, Ma YT, Yang YN, Li XM, Ma X, ZY F, Zheng YY, Chen BD, Liu F (2013) CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population. PLoS One 8(3):e59344. https:\/\/doi.org\/10.1371\/journal.pone.0059344","journal-title":"PLoS One"},{"issue":"3","key":"2393_CR33","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/tpj.2010.21","volume":"11","author":"F Sofi","year":"2011","unstructured":"Sofi F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF (2011) Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J 11(3):199\u2013206. https:\/\/doi.org\/10.1038\/tpj.2010.21","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"2393_CR34","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1373\/clinchem.2016.255232","volume":"63","author":"K Friede","year":"2017","unstructured":"Friede K, Li J, Voora D (2017) Use of pharmacogenetic information in the treatment of cardiovascular disease. Clin Chem 63(1):177\u2013185. https:\/\/doi.org\/10.1373\/clinchem.2016.255232","journal-title":"Clin Chem"},{"issue":"1","key":"2393_CR35","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/tpj.2014.28","volume":"15","author":"JP Depta","year":"2015","unstructured":"Depta JP, Lenzini PA, Lanfear DE, Wang TY, Spertus JA, Bach RG, Cresci S (2015) Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction. Pharmacogenomics J 15(1):20\u201325. https:\/\/doi.org\/10.1038\/tpj.2014.28","journal-title":"Pharmacogenomics J"},{"issue":"3","key":"2393_CR36","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1161\/CIRCGENETICS.113.000303","volume":"7","author":"S Cresci","year":"2014","unstructured":"Cresci S, Depta JP, Lenzini PA, Li AY, Lanfear DE, Province MA, Spertus JA, Bach RG (2014) Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction. Circ Cardiovasc Genet 7(3):277\u2013286. https:\/\/doi.org\/10.1161\/CIRCGENETICS.113.000303","journal-title":"Circ Cardiovasc Genet"},{"issue":"22","key":"2393_CR37","doi-asserted-by":"publisher","first-page":"210e","DOI":"10.1161\/01.CIR.0000076180.03211.BD","volume":"107","author":"M Shechter","year":"2003","unstructured":"Shechter M (2003) Atorvastatin and the ability of clopidogrel to inhibit platelet aggregation. Circulation 107(22):210e\u20132210. https:\/\/doi.org\/10.1161\/01.CIR.0000076180.03211.BD","journal-title":"Circulation"},{"issue":"2","key":"2393_CR38","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1159\/000320093","volume":"117","author":"LA Malek","year":"2010","unstructured":"Malek LA, Przyluski J, Spiewak M, Klopotowski M, Kostrzewa G, Kruk M, Ploski R, Witkowski A, Ruzyllo W (2010) Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction. Cardiology 117(2):81\u201387. https:\/\/doi.org\/10.1159\/000320093","journal-title":"Cardiology"},{"issue":"1","key":"2393_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clpt.2005.10.002","volume":"79","author":"SC Sim","year":"2006","unstructured":"Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79(1):103\u2013113. https:\/\/doi.org\/10.1016\/j.clpt.2005.10.002","journal-title":"Clin Pharmacol Ther"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-017-2393-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-017-2393-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-017-2393-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T19:39:10Z","timestamp":1751139550000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-017-2393-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,14]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["2393"],"URL":"https:\/\/doi.org\/10.1007\/s00228-017-2393-1","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,14]]}}}